FDA PV Guidance vs EU GMP Annex 15
The US lifecycle guidance vs the EU qualification-and-validation annex.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
The FDA’s 2011 process-validation guidance frames validation as a three-stage lifecycle (design, qualification, continued verification). EU GMP Annex 15 covers qualification and validation more broadly — DQ/IQ/OQ/PQ, process validation, cleaning validation, and more. They are strongly aligned in the lifecycle philosophy, with differences in structure and terminology.
| ASPECT | FDA PV GUIDANCE | EU GMP ANNEX 15 |
|---|---|---|
| Form | A guidance document (recommendations) | A GMP annex (given legal force) |
| Core model | Three-stage lifecycle (design → PPQ → CPV) | Qualification (DQ/IQ/OQ/PQ) + validation, lifecycle-aware |
| Scope | Process validation for drugs | Qualification + validation broadly (incl. cleaning, utilities) |
| Ongoing verification | Continued process verification (Stage 3) | Ongoing process verification / periodic review |
| Terminology | PPQ, CQAs, CPPs, CPV | DQ/IQ/OQ/PQ, PV, revalidation |
Follow the FDA guidance for US-market products — it structures process validation as design, qualification (PPQ), and continued verification, and is what FDA inspectors expect.
Follow EU GMP Annex 15 for EU-market products — it is the legally-backed annex covering qualification and validation, including cleaning validation and requalification, in a lifecycle-aware way.
Same lifecycle philosophy, different documents: the FDA guidance is US recommendations framed as three stages; Annex 15 is an EU GMP annex covering qualification and validation with legal force. A global validation programme designs to both — the concepts (design, qualify, continuously verify) are aligned, so the practical differences are structure, terminology, and Annex 15’s broader scope (e.g., utilities and cleaning validation in one place).
FDA PV Guidance vs EU GMP Annex 15: frequently asked questions
Common questions on how FDA PV Guidance and EU GMP Annex 15 differ and when each applies.
Are the FDA process-validation guidance and EU Annex 15 compatible?
Yes — they share the lifecycle philosophy (design, qualify, then continuously verify). A single validation programme can satisfy both; the differences are in document structure, terminology (PPQ/CPV vs DQ/IQ/OQ/PQ), and Annex 15’s broader scope.
Which covers cleaning validation?
EU GMP Annex 15 explicitly addresses cleaning validation and requalification within its scope. The FDA’s 2011 guidance focuses on process validation; cleaning validation is addressed through other FDA guidance and cGMP expectations.
Is the FDA guidance legally binding?
FDA guidance documents describe the agency’s current thinking and are not themselves binding regulation, though they reflect how FDA interprets the cGMP requirements it will inspect against. Annex 15 is part of EU GMP and carries legal force through the GMP framework.